Our client Amgen Presents New Data On Talimogene Laherparepvec As Single Agent And Combination Therapy In Metastatic Melanoma At ASCO
- 0 Comments
- Topic: Healthcare, Pharma, news
Bispecific T cell Engager (BiTE®) technology is designed to bind polyclonal cytotoxic T cells and targeted malignant cells1,2,8
Search by Style
Whiteboard